cultivate(MD) Capital Funds LP Announces Investment into Nanochon

2023-11-27

GRAND RAPIDS, Mich., Nov. 27, 2023 /PRNewswire/ -- cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator.

Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration. Nanochon's Chondrograft™ replaces lost or damaged cartilage and encourages new growth using an innovative material and 3D printed designs that are cost-effective and easy to deploy treatment options.

cultivate(MD) Capital Funds focus on investments into early-stage medical device companies with innovative technologies.

Post this

R. Sean Churchill, MD, MBA, Managing Director of cultivate(MD) said, "cultivate(MD) is proud to announce their investment in the Series Seed Prime round for Nanochon. Over the past six years, cultivate(MD) Capital Funds has focused our efforts to help develop emerging technology that solves previously unsolvable healthcare conditions. Nanochon fits this description perfectly as they address focal cartilage defects in the 18-55 year old active patient population. Their novel implant has demonstrated unparalleled results in numerous equine studies and is in final preparation for first-in-human trials. cultivate(MD) is proud to partner with Nanochon to help bring this technology to the forefront, and I am pleased to have been appointed to serve on Nanochon's Board of Directors to represent cultivate(MD) Capital.

Benjamin Holmes, PhD, CEO of Nanochon said, "We at Nanochon are thrilled to welcome cultivate(MD) as a key investor and valued member of our Board of Directors. Their investment and board participation represent a significant vote of confidence in our vision and technology. This collaboration is a crucial step towards accelerating our groundbreaking work in revolutionizing joint health and regenerative treatments and will enable us to establish a new standard in minimally invasive, durable, and restorative treatments."

About cultivate(MD) Capital Funds

As a medical device venture capital fund, cultivate(MD) is dedicated to bringing emerging health care innovations to market, with a special focus on medical device and orthopedic technologies. cultivate(MD) is focused on investing in early stage healthcare companies with innovative technologies that have demonstrated evidence of effectiveness. For more information, visit: https://cultivate-md.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations, assumptions, and other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date on which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions.

SOURCE cultivate(MD)

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构